Gene Fusion Testing

Gene fusion testing identifies rearrangements that can help characterize cancers, support diagnosis, inform targeted treatment selection, and guide disease monitoring. Its role is expanding as precision oncology increasingly depends on molecular evidence rather than histology alone. Adoption is shaped by clinical utility, assay quality, tissue availability, reimbursement, laboratory capability, and the ability to translate results into treatment decisions.

The testing landscape is shifting from single-gene assays toward broader approaches that can detect known and novel fusions across multiple cancer types. RNA-based sequencing, DNA/RNA hybrid workflows, fluorescence in situ hybridization, polymerase chain reaction, and immunohistochemistry each address different clinical and operational needs. Laboratories are therefore emphasizing fit-for-purpose testing, orthogonal confirmation, standardized interpretation, and integration with pathology and electronic health-record workflows. Liquid biopsy and testing of limited or degraded specimens are also increasing interest, although sensitivity, validation, and clinical evidence remain important constraints.

Artificial intelligence can support gene fusion testing by improving image interpretation, prioritizing candidate rearrangements, assisting sequence-quality review, and linking molecular findings with pathology and clinical context. Its most practical near-term value is workflow augmentation: reducing manual review, flagging discordant results, and helping laboratories manage complex variant evidence. Reliable deployment still requires representative validation datasets, transparent performance monitoring, human oversight, cybersecurity controls, and clear responsibility for final reporting. AI is most useful when embedded within validated laboratory processes rather than treated as an independent diagnostic authority.

North America benefits from advanced molecular laboratories, broad oncology networks, and established clinical adoption, while reimbursement variation and evidence requirements influence utilization. Europe combines strong academic and public-health capabilities with differing national pathways, procurement practices, and access conditions across the European Union and neighboring markets. Asia-Pacific presents major opportunities alongside substantial variation in laboratory infrastructure, specialist availability, and regulatory maturity; Australia, China, India, Japan, and South Korea illustrate distinct health-system approaches. Latin America is advancing through reference laboratories and specialized cancer centers, but geographic concentration and funding constraints can limit access. The Middle East is strengthening precision-oncology capacity, particularly through tertiary institutions and GCC collaboration, while Africa continues to face challenges involving equipment, sample logistics, trained personnel, and equitable access to validated testing.

ASEAN countries are developing molecular oncology capacity at different speeds, making referral networks, shared quality standards, and workforce development important. BRICS economies combine substantial scientific capability with varied regulatory, reimbursement, and infrastructure environments, creating a need for locally adaptable testing pathways. The European Union benefits from cross-border scientific collaboration but must continue addressing national differences in access, data governance, and laboratory accreditation. G7 members generally possess mature diagnostic ecosystems, yet integration, affordability, and equitable access remain priorities. GCC states are investing in advanced healthcare infrastructure and can accelerate adoption through coordinated procurement and specialist networks. NATO members span diverse health systems, so interoperability, resilient supply chains, and common quality principles are strategically relevant.

The United States and Canada have strong oncology and laboratory ecosystems, with implementation shaped by validation, payer policy, and access across regions. The United Kingdom, France, Germany, Italy, and Spain are integrating molecular testing through national or regional health structures, while balancing centralized standards with local capacity. Australia combines sophisticated pathology services with geographic access challenges. China, Japan, and South Korea continue expanding precision-oncology capabilities through advanced hospitals, research networks, and domestic diagnostic development. India is broadening access through tertiary centers and reference laboratories, although affordability and uneven infrastructure remain important considerations. Brazil and Mexico are building capacity amid regional disparities and funding constraints. Russia’s pathway is influenced by institutional capabilities, regulatory conditions, and access to specialized laboratories.

Industry leaders should align assay selection with the clinical question, specimen type, turnaround-time requirement, and available tissue. They should invest in quality management, external proficiency testing, orthogonal confirmation where appropriate, and reports that clearly connect findings with evidence and treatment implications. Partnerships among pathology, oncology, laboratory medicine, and informatics teams can reduce workflow fragmentation. Leaders should also establish transparent AI governance, strengthen data and cybersecurity controls, develop referral models for underserved areas, and document clinical utility for payers and health systems. Regional strategies should account for local regulation, reimbursement, sample transport, workforce capability, and patient consent requirements rather than assuming a single global operating model.

This executive summary uses a structured qualitative assessment of gene fusion testing across technologies, clinical workflows, health systems, and geographies. The analysis considers peer-reviewed evidence, clinical guidelines, regulatory principles, laboratory quality practices, oncology implementation experience, and publicly documented health-system conditions. Findings are synthesized by region, multinational group, and country to identify recurring drivers, barriers, and operational priorities. No market estimates, market shares, forecasts, or company-specific claims are used. Interpretations should be revisited as assay validation standards, clinical evidence, reimbursement policies, and data-governance requirements evolve.

Gene fusion testing is becoming an important component of precision oncology, but its value depends on more than technical detection. Reliable results, appropriate specimen handling, expert interpretation, timely reporting, and access to actionable care must operate as one connected pathway. Organizations that combine validated multi-modal testing with strong quality systems, responsible AI, interoperable data practices, and regionally appropriate delivery models will be better positioned to convert molecular findings into meaningful clinical decisions.